SAFETY PROFILE OF UPADACITINIB IN RHEUMATOID ARTHRITIS: INTEGRATED ANALYSIS FROM THE SELECT PHASE 3 CLINICAL PROGRAMME

被引：0
|
作者：
Cohen, Stanley B. [1 ]
van Vollenhoven, Ronald [2 ]
Winthrop, Kevin [3 ]
Zerbini, Cristiano [4 ]
Tanaka, Yoshiya [5 ]
Bessette, Louis [6 ]
Zhang, Ying [7 ]
Khan, Nasser [7 ]
Hendrickson, Barbara [7 ]
Enejosa, Jeffrey V. [7 ]
Burmester, Gerd Rudiger [8 ]
机构：
[1] Metroplex Clin Res Ctr, Dallas, TX USA
[2] ARC, Amsterdam Rheumatol & Immunol Ctr, Amsterdam, Netherlands
[3] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA
[4] Ctr Paulista Invest Clin, CEPIC, Sao Paulo, Brazil
[5] Univ Occupat & Environm Hlth, Dept Internal Med 1, Kitakyushu, Japan
[6] Laval Univ, Fac Med, Quebec City, PQ, Canada
[7] AbbVie Inc, Waukegan Rd, N Chicago, IL USA
[8] Charite, Dept Rheumatol & Clin Immunol, Berlin, Germany
来源：
RHEUMATOLOGY | 2020年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P209
引用
收藏
页码：96 / 96
页数：1
相关论文
共 50 条
  • [41] Safety Profile of Upadacitinib up to 6.5 Years of Exposure in Patients with Rheumatoid Arthritis
    Cohen, S. B.
    van Vollenhofen, R.
    Curtis, J. R.
    Calabrese, L.
    Zerbini, C. A. F.
    Bessette, L.
    Richez, C.
    Strenholt, S.
    Coombs, D.
    Khan, N.
    Gara, A.
    Burmester, G. R.
    SWISS MEDICAL WEEKLY, 2023, 153 : 25S - 25S
  • [42] SAFETY PROFILE OF UPADACITINIB UP TO 6.5 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Cohen, S. B.
    Van Vollenhoven, R.
    Curtis, J.
    Calabrese, L.
    Zerbini, C.
    Tanaka, Y.
    Bessette, L.
    Richez, C.
    Strengholt, S.
    Coombs, D.
    Khan, N.
    Gara, A.
    Burmester, G. R.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 709 - 710
  • [43] TREATING RHEUMATOID ARTHRITIS PATIENTS WITH MODERATE DISEASE ACTIVITY: AN ANALYSIS OF THE UPADACITINIB SELECT PHASE III RANDOMISED STUDIES
    Conaghan, Phillip G.
    Pavelka, Karel
    Hsieh, Song-Chou
    Bonnington, Terri-Leigh
    Kent, Toby C.
    Edwards, Christopher J.
    RHEUMATOLOGY, 2021, 60
  • [44] SIRUKUMAB INTEGRATED SAFETY IN RHEUMATOID ARTHRITIS PATIENTS: ANALYSIS OF THE SIRROUND PHASE 3 DATA
    Aletaha, D.
    Thorne, C.
    Schiff, M.
    Harigai, M.
    Rao, R.
    Goldstein, N.
    Cheng, B.
    Cohen, C.
    Hsu, B.
    Brown, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 845 - 845
  • [45] INTEGRATED SAFETY DATA ANALYSIS ACROSS PHASE 3 CLINICAL STUDIES FOR INTRAVENOUS GOLIMUMAB IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND ANKYLOSING SPONDYLITIS
    Husni, M. E.
    Schwartzman, S.
    Deodhar, A.
    Kafka, S.
    Chakravarty, S. D.
    Hsia, E. C.
    Harrison, D. D.
    Leu, J. H.
    Zhou, Y.
    Lo, K. H.
    Kavanaugh, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 608 - 609
  • [46] SAFETY AND EFFECTIVENESS OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 48 WEEKS FROM THE SELECT-COMPARE STUDY
    Fleischmann, Roy
    Enejosa, Jeffrey
    Song, In-Ho
    Mysler, Eduardo
    Bessette, Louis
    Peterfy, Charles
    Durez, Patrick
    Ostor, Andrew
    Li Yihan
    Zhou, Yijie
    Genovese, Mark C.
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 744 - 745
  • [47] INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS
    Genovese, M. C.
    Winthrop, K.
    Tanaka, Y.
    Takeuchi, T.
    Kivitz, A.
    Matzkies, F.
    Ye, L.
    Jiang, D.
    Guo, Y.
    Bartok, B.
    Besuyen, R.
    Burmester, G. R.
    Gottenberg, J. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 320 - 321
  • [48] Integrated safety analysis of filgotinib treatment for rheumatoid arthritis from seven clinical trials
    Nash, P.
    Loftus, E.
    Genovese, M.
    Winthrop, K.
    Tanaka, Y.
    Takeuchi, T.
    Kivitz, A.
    Matzkies, F.
    Ye, L.
    Jiang, D.
    Guo, Y.
    Bartok, B.
    Besuyen, R.
    Burmester, G.
    Gottenberg, J-E
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 130 - 130
  • [49] Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program
    Peterfy, Charles G.
    Strand, Vibeke
    Friedman, Alan
    Hall, Stephen
    Mysler, Eduardo
    Durez, Patrick
    Baraliakos, Xenofon
    Enejosa, Jeffrey, V
    Shaw, Tim
    Li, Yihan
    Chen, Su
    Song, In-Ho
    RHEUMATOLOGY, 2022, 61 (08) : 3246 - 3256
  • [50] LONG-TERM SAFETY PROFILE OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, OR ANKYLOSING SPONDYLITIS
    Nash, Peter
    Burmester, Gerd R.
    Cohen, Stanley B.
    Winthrop, Kevin
    Rubbert-Roth, Andrea
    Deodhar, Atul
    Elkayam, Ori
    Mysler, Eduardo
    Tanaka, Yoshiya
    Liu, Jianzhong
    Lacerda, Ana P.
    Pierre-Louis, Bosny J.
    Shaw, Tim
    Mease, Philip J.
    INTERNAL MEDICINE JOURNAL, 2022, 52 : 27 - 27
12345